透析療法ネクスト　XV

出版社： 医学図書出版
著者：
発行日： 2013-07-01
分野： 臨床医学：内科  >  腎臓
ISBN： 9784865170160
電子書籍版： 2013-07-01
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,860 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,430 円(税込)

購入する

目次

  • 透析療法ネクスト　XV

    ―目次―

    座談会
    　高リン血症治療におけるポリマー製剤の果たす役割

    特集　透析患者のCKD-MBD治療最前線
    　JSDTガイドラインについて
    　透析患者における血管石灰化
    　血管石灰化と心血管合併症
    　高リン血症治療薬の果たす役割
    　病診連携・院内連携（メディカルスタッフの果たす役割）
    　新規高リン血症治療薬ビキサロマー（キックリンカプセル）の
    　　薬理学的特性
    　ビキサロマー：臨床開発試験成績
    　実臨床におけるビキサロマー使用経験
    　　―塩酸セベラマーからの同用量切り替え―
    　ビキサロマーの効果的な使い方
    　血液透析患者へのビキサロマー（キックリン）の使用経験
    　当院における高リン血症治療薬ビキサロマーと
    　　塩酸セベラマーとの比較検討
    　ビキサロマーへの今後の期待
    　透析療法の歴史(15)―透析液清浄化の意義とその変遷―

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

特集 透析患者のCKD - MBD治療最前線

P.21 掲載の参考文献
1) Kidney Disease : Improving Global Outcomes (KDIGO) CKD-MBD Work Group : KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney IntSuppl 113 : S1-130, 2009
PubMed
2) Massry S : K/DOQI Clinical Practice Guidelines. Am J Kidney Dis 42 (Suppl 3) : S1-201, 2003
 
3) 日本透析医学会 : 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 日透析医学会誌 39 : 1435-1455, 2006
 
4) Payne RB, Little AJ, Williams RB, et al : Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4 : 643-646, 1973
PubMed
5) Yokoyama K, Katot N, Kubo H, et al : Clinical significance of the K/DOQI bone guidelines in Japan. Am J Kidney Dis 44 : 383-384, 2004
 
6) Fukagawa M, Yumita S, Akizawa T, et al : Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23 : 328-335, 2008
PubMed
7) Ohashi N, Uematsu T, Nagashima S, et al : The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br J Clin Pharmacol 57 : 726-734, 2004
PubMed
8) Shoji T, Shinohara K, Kimoto E, et al : Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19 : 179-184, 2004
 
9) Teng M, Wolf M, Ofsthun MN, et al : Activated injectable vitamin D and hemodialysis survival : a historical cohort study. J Am Soc Nephrol 16 : 1115-1125, 2005
PubMed
10) Kalantar-Zadeh K, Kuwae N, Regidor DL, et al : Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70 : 771-780, 2006
PubMed
11) Tentori F, Hunt WC, Stidley CA, et al : Medical Directors of Dialysis Clinic Inc. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70 : 1858-1865, 2006
PubMed
12) Kovesdy CP, Ahmadzadeh S, Anderson JE, et al : Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 168 : 397-403, 2008
PubMed
13) Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, et al : Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 74 : 1070-1078, 2008
PubMed
14) Fukagawa M, Komaba H, Onishi Y, et al : Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan : baseline data from the MBD-5D. Am J Nephrol 33 : 427-437, 2011
PubMed
P.28 掲載の参考文献
1) Contiguglia SR, Alfrey AC, Miller NL, et al : Nature of soft tissue calcification in uremia. Kidney Int 4 : 229-235, 1973
PubMed
2) Schlieper G, Aretz A, Verberckmoes SC, et al : Ultrastructural analysis of vascular calcifications in uremia. J Am Soc Nephrol 21 : 689-696, 2010
PubMed
3) Mohler ER 3rd : Vascular calcification : good, bad or ugly? Vasc Med 7 : 161-162, 2002
PubMed
4) Hunt JL, Fairman R, Mitchell ME, et al : Bone formation in carotid plaques : a clinicopathological study. Stroke 33 : 1214-1219, 2002
PubMed
5) McCullough PA, Sandberg KR, Dumler F, et al : Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease : a systematic review. J Nephrol 17 : 205-215, 2004
PubMed
6) Chertow GM : Slowing the progression of vascular calcification in hemodialysis. J Am Soc Nephrol 14 : S310-314, 2003
PubMed
7) Tyson KL, Reynolds JL, McNair R, et al : Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 23 : 489-494, 2003
PubMed
8) Shanahan CM, Cary NR, Metcalfe JC, et al : High expression of genes for calcification-regulating Proteins in human atherosclerotic plaques. J Clin Invest 93 : 2393-2402, 1994
PubMed
9) Mizobuchi M, Towler D, Slatopolsky E : Vascular calcification : the killer of patients with chronic kidney disease. J Am Soc Nephrol 20 : 1453-1464, 2009
PubMed
10) Shroff R, Long DA, Shanahan C : Mechanistic Insights into Vascular Calcification in CKD. J Am Soc Nephrol 24 : 179-189, 2013
PubMed
11) Chung AW, Yang HH, Kim JM, et al : Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease. Circulation 120 : 792-801, 2009
PubMed
12) Imura A, Iwano A, Tohyama O, et al : Secreted Klotho protein in sera and CSF : implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 565 : 143-147, 2004
PubMed
13) Yamamoto M, Clark JD, Pastor JV, et al : Regulation of oxidative stress by the antiaging hormone klotho. J Biol Chem 280 : 38029-38034, 2005
PubMed
14) Saito Y, Yamagishi T, Nakamura T, et al : Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 248 : 324-329, 1998
PubMed
15) Hu MC, Shi M, Zhang J, et al : Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 22 : 124-136, 2011
PubMed
16) Lim K, Lu TS, Molostvov G, et al : Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 125 : 2243-2255, 2012
PubMed
17) Kanno Y, Into T, Lowenstein CJ, et al : Nitric oxide regulates vascular calcification by interfering with TGF-signalling. Cardiovasc Res 77 : 221-230, 2008
PubMed
18) Wu SY, Zhang BH, Pan CS, et al : Endothelin-1 is a potent regulator in vivo in vascular calcification and in vitro in calcification of vascular smooth muscle cells. Peptides 24 : 1149-1156, 2003
PubMed
19) Long DA, Norman JT, Fine LG : Restoring the renal microvasculature to treat chronic kidney disease. Nat Rev Nephrol 8 : 244-250, 2012
PubMed
20) David S, John SG, Jefferies HJ, et al : Angiopoietin-2 levels predict mortality in CKD patients. Nephrol Dial Transplant 27 : 1867-1872, 2012
 
21) Mikhaylova L, Malmquist J, Nurminskaya M : Regulation of in vitro vascular calcification by BMP4, VEGF and Wnt3a. Calcif Tissue Int 81 : 372-381, 2007
PubMed
P.39 掲載の参考文献
1) London GM, Guerin AP, Marchais SJ, et al : Arterial media calcification in end-stage renal disease : impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18 : 1731-1740, 2003
PubMed
2) Hassan NA, D'Orsi ET, D'Orsi CJ, et al : The risk for medial arterial calcification in CKD. Clin J Am Soc Nephrol 7 : 275-279, 2012
 
3) Duhn V, D'Orsi ET, Johnson S, et al : Breast arterial calcification : a marker of medial vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 6 : 377-382, 2011
PubMed
4) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 323-348, 2012
 
5) Kidney Disease : Improving Global Outcomes (KDIGO) CKD-MBD Work Group : KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl : S1-130, 2009
PubMed
6) Kim HG, Song SW, Kim TY, et al : Risk factors for progression of aortic arch calcification in patients on maintenance hemodialysis and peritoneal dialysis. Hemodial Int 15 : 460-467, 2011
PubMed
7) Noordzij M, Cranenburg EM, Engelsman LF, et al : NECOSAD Study Group. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transplant 26 : 1662-1669, 2011
 
8) Yamada K, Fujimoto S, Nishiura R, et al : Risk factors of the progression of abdominal aortic calcification in patients on chronic haemodialysis, Nephrol Dial Transplant 22 : 2032-2037, 2007
PubMed
9) Khan AM, Chirinos JA, Litt H, et al : FGF-23 and the Progression of Coronary Arterial Calcification in Patients New to Dialysis. Clin J Am Soc Nephrol 7 : 2017-2022, 2012
PubMed
10) Ozkok A, Caliskan Y, Sakaci T, et al : Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. Clin J Am Soc Nephrol 7 : 965-973, 2012
PubMed
11) Ishimura E, Okuno S, Kitatani K, et al : Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients-importance of glycaemic control. Diabetologia 45 : 1446-1448, 2002
PubMed
12) Yamada S, Inaba M, Shidara K, et al : Association of glycated albumin, but not glycated hemoglobin, with peripheral vascular calcification in hemodialysis patients with type 2 diabetes. Life Sci 83 : 516-519, 2008
 
13) Nakamura S, Ishibashi-Ueda H, Niizuma S, et al : Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol 4 : 1892-1900, 2009
PubMed
14) Inoue T, Ogawa T, Ishida H, et al : Aortic arch calcification evaluated on chest X-ray is a strong independent predictor of cardiovascular events in chronic hemodialysis patients. Heart Vessels 27 : 135-142, 2012
 
15) Abdelmalek JA, Stark P, Walther CP, et al : Associations between coronary calcification on chest radiographs and mortality in hemodialysis patients. Am J Kidney Dis 60 : 990-997, 2012
PubMed
16) Okuno S, Ishimura E, Kitatani K, et al : Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis 49 : 417-425, 2007
PubMed
17) Verbeke F, Van Biesen W, Honkanen E, et al : CORD Study Investigators. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients : outcome of the calcification outcome in renal disease (CORD) study. Clin J Am Soc Nephrol 6 : 153-159, 2011
 
18) Blacher J, Guerin AP, Pannier B, et al : Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38 : 938-942, 2001
PubMed
19) Adragao T, Pires A, Lucas C, et al : A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 19 : 1480-1488, 2004
 
20) Jean G, Bresson E, Terrat JC, et al : Peripheral vascular calcification in long-haemodialysis patients : associated factors and survival consequences. Nephrol Dial Transplant 24 : 948-955, 2009
PubMed
21) Ohya M, Otani H, Kimura K, et al : Vascular calcification estimated by aortic calcification area index is a significant predictive parameter of cardiovascular mortality in hemodialysis patients. Clin Exp Nephrol 15 : 877-883, 2011
PubMed
22) Matsuoka M, Iseki K, Tamashiro M, et al : Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 8 : 54-58, 2004
PubMed
23) Ohtake T, Ishioka K, Honda K, et al : Impact of coronary artery calcification in hemodialysis patients : Risk factors and associations with prognosis. Hemodial Int 14 : 218-225, 2010
PubMed
24) Shantouf RS, Budoff MJ, Ahmadi N, et al : Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients. Am J Nephrol 31 : 419-425, 2010
PubMed
25) Caliskan Y, Demirturk M, Ozkok A, et al : Coronary artery calcification and coronary flow velocity in haemodialysis patients. Nephrol Dial Transplant 25 : 2685-2690, 2010
PubMed
26) Coen G, Pierantozzi A, Spizzichino D, et al : Risk factors of one year increment of coronary calcifications and survival in hemodialysis patients. BMC Nephrol 11 : 10, 2010
PubMed
27) Nakayama M, Ura Y, Nagata M, et al : Carotid artery calcification at the initiation of hemodialysis is a risk factor for cardiovascular events in patients with end-stage renal disease : a cohort study. BMC Nephrol 12 : 56, 2011
PubMed
28) Wang AY, Wang M, Woo J, et al : Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients : a prospective study. J Am Soc Nephrol 14 : 159-168, 2003
PubMed
29) Raggi P, Bellasi A, Gamboa C, et al : Allcause mortality in hemodialysis patients with heart valve calcification. Clin J Am Soc Nephrol 6 : 1990-1995, 2011
PubMed
30) Takahashi H, Ishii H, Aoyama T, et al : Association of Cardiac Valvular Calcifications and C-Reactive Protein With Cardiovascular Mortality in Incident Hemodialysis Patients : A Japanese Cohort Study. Am J Kidney Dis 61 : 254-261, 2013
 
31) Chertow GM, Burke SK, Raggi P : Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 : 245-252, 2002
 
32) Block GA, Spiegel DM, Ehrlich J, et al : Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 : 1815-1824, 2005
PubMed
33) Qunibi W, Moustafa M, Muenz LR, et al : CARE-2 Investigators. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control : the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51 : 952-965, 2008
 
34) Kakuta T, Tanaka R, Hyodo T, et al : Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 57 : 422-431, 2011
PubMed
35) Toussaint ND, Lau KK, Polkinghorne KR, et al : Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis : A pilot randomized controlled trial. Nephrology (Carlton) 16 : 290-298, 2011
PubMed
36) Raggi P, Chertow GM, Torres PU, et al : ADVANCE Study Group. The ADVANCE study : a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26 : 1327-1339, 2011
 
37) Matias PJ, Ferreira C, Jorge C, et al : 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol Dial Transplant 24 : 611-618, 2009
PubMed
38) Shroff R, Egerton M, Bridel M, et al : Abimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 19 : 1239-1246, 2008
 
39) Mathew S, Lund RJ, Chaudhary LR, et al : Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 19 : 1509-1519, 2008
 
40) Lau WL, Leaf EM, Hu MC, et al : Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 82 : 1261-1270, 2012
PubMed
41) Shoji T, Shinohara K, Kimoto E, et al : Lower risk for cardiovascular mortality in oral lalpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19 : 179-184, 2004
 
42) Ogawa T, Ishida H, Akamatsu M, et al : Relation of oral 1alpha-hydroxy vitamin D3 to the progression of aortic arch calcification in hemodialysis patients. Heart Vessels 25 : 1-6, 2010
 
43) Fusaro M, Noale M, Viola V, et al : Vitamin K Italian (VIKI) Dialysis Study lnvestigators. Vitamin K, vertebral fractures, vascular calcifications, and mortality : Vitamin K Italian (VIKI) dialysis study. J Bone Miner Res 27 : 2271-2278, 2012
PubMed
44) Westenfeld R, Krueger T, Schlieper G, et al : Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients : a randomized trial. Am J Kidney Dis 59 : 186-195, 2012
PubMed
45) Hashiba H, Aizawa S, Tamura K, et al : Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients : long-term effects. Ther Apher Dial 10 : 59-64, 2006
PubMed
46) Nitta K Akiba T, Suzuki K, et al : Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44 : 680-688, 2004
 
47) Adirekkiat S, Sumethkul V, Ingsathit A, et al : Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. Nephrol Dial Transplant 25 : 1923-1929, 2010
PubMed
P.55 掲載の参考文献
1) Moe S, Drueke T, Cunningham J, et al : Kidney Disease : Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006
PubMed
2) Isakova T, Wahl P, Vargas GS, et al : Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79 : 1370-1378, 2011
 
3) Alfrey AC : Effect of dietary phosphate restriction on renal function and deterioration. Am J Clin Nutr 47 : 153-156, 1988
PubMed
4) Kestenbaum B, Sampson JN, Rudser KD, et al : Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16 : 520-528, 2005
PubMed
5) Block GA, Klassen PS, Lazarus JM, et al : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 : 2208-2218, 2004
PubMed
6) Nakai S, Akiba T, Kazama J, et al : Effects of serum calcium, phosphorus, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 12 : 49-54, 2008
PubMed
7) Isakova T, Whal P, Vargas GS, et al : Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79 : 1370-1378, 2011
 
8) Larsson T, Nisbeth U, Ljunggren O, et al : Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64 : 2272-2279, 2003
 
9) Slatopolsky E, Finch J, Denda M, et al : Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97 : 2534-2540, 1996
PubMed
10) Regidor DL, Kovesdy CP, Mehrotra R, et al : Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 19 : 2193-2203, 2008
 
11) Jono S, McKee MD, Murry CE, et al : Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87 : E10-17, 2000
PubMed
12) Son BK, Kozaki K, Iij ima K, et al : Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ Res 98 : 1024-1031, 2006
 
13) Kuro-O M : Phosphate and Klotho. Kidney Int 121 (Suppl) : S20-S23, 2011
PubMed
14) Ohnishi M, Razzaque MS : Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J 24 : 3562-3571, 2010
PubMed
15) Wolf M : Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21 : 1427-1435, 2010
PubMed
16) Faul C, Amaral AP, Oskouei B, et al : FGF23 induces left ventricular hypertrophy. J Clin Invest 121 : 4393-4408, 2011
PubMed
17) Block GA, Hulbert-Shearon TE, Levin NW, et al : Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients : a national study. Am J Kidney Dis 31 : 607-617, 1998
PubMed
18) Young EW, Albert JM, Satayathum S, et al : Predictors and consequences of altered mineral metabolism : the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67 : 1179-1187, 2005
 
19) Kalantar-Zadeh K, Kuwae N, Regidor DL, et al : Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70 : 771-780, 2006
PubMed
20) Tonelli M, Sacks F, Pfeffer M, et al : Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112 : 2627-2633, 2005
PubMed
21) National Kidney Foundation : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3) : S1-S201, 2003
 
22) Shinaberger CS, Kilpatrick RD, Regidor DL, et al : Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kidney Dls 48 : 37-49, 2006
 
23) Colman S, Bross R, Benner D, et al : The Nutritional and Inflammatory Evaluation in Dialysis patients (NIED) study : Overview of the NIED study and the role of dietitians. J Ren Nutr 15 : 231-243, 2005
PubMed
24) Shinaberger CS, Greenkand S, Kopple JD, et al : Is controlling Phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 88 : 1511-1518, 2008
PubMed
25) Hardy P, Sechet A, Hottelart C, et al : Inhibition of gastric section by omeprazole and effciency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs 22 : 569-573, 1998
 
26) London GM, Marchais SJ, Guerin AP, et al : Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 19 : 1827-1835, 2008
 
27) Blacher J, Guerin AP, Pannier B, et al : Arterial calcifications, Arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertention 38 : 938-942, 2001
 
28) Guiren AP, London GM, Marchais SJ, et al : Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15 : 1014-1021, 2000
 
29) Koiwa F, Onoda N, Kato H, et al : Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate therapy for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 9 : 340-346, 2005
PubMed
30) Chertow GM, Burke SK, Raggi P : Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 : 245-252, 2002
PubMed
31) Hutchinson AJ, Laville M : Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant 23 : 3677-3684, 2008
 
32) Shigematsu T : Multicenter prospective randomized, double blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol 70 : 404-410, 2008
PubMed
33) D'Haese PC, Spasovski GB, Sikole A, et al : A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 85 (Suppl) : S73-S78, 2003
PubMed
34) Altmann P, Barnett ME, Finn WF : Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis : No adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int 71 : 252-259, 2007
PubMed
35) Hutchinson AJ, Barnett ME, Krause R, et al : Long-term ef6cacy and safety profile of lanthanum carbonate : results for up to 6 years of treatment. Nephron Clin Pract 110 : c15-c23, 2008
 
36) Salusky IB, Goodman WG, Sahney S, et al : Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 16 : 2501-2508, 2005
PubMed
37) Ferreira A, Frazao JM, Monier-Faugere MC, et al : Effects of sevelamer hydrochloride and calcium carbonate on renal osteo. dystrophy in hemodialysis patients. J Am Soc Nephrol 19 : 405-412, 2008
 
38) Barreto DV, Barreto Fde C, de Carvalho AB, et al : Phosphate binder impact on bone remodeling and coronary calcificationresults from the BRiC study. Nephron Clin Pract 110 : c273-c283, 2008
 
39) Freemont AJ, Hayland JA, Denton J : The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 64 : 428-437, 2005
 
40) Spasovski GB, Sikole A, Gelev S, et al : Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow up. Nephrol Dial Transplant 21 : 2217-2224, 2006
PubMed
41) Malluche HH, Simai GA, Swanepoel C, et al : Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 70 : 284-295, 2008
 
42) Shigematsu T, Tokumoto A, Nakaoka A, et al : Effect of lanthanum carbonate on bone in Japanese dialysis patients with hyperparathyroidism. Ther Apher Dial 12 : 55-61, 2010
 
43) Damment S, Secker R, Shen V, et al : Longterm treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure. Nephrol Dial transplant 26 : 1803-1812, 2011
PubMed
44) Block GA, Spiegel DM, Ehrlich J, et al : Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 : 1815-1824, 2005
PubMed
45) Russo D, Miranda I, Ruocco C, et al : The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72 : 1255-1261, 2007
PubMed
46) Qunibi W, Moustafa M, Muenz LR, et al : A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control : the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51 : 952-965, 2008
PubMed
47) Caglar K, Yilmaz MI, Saglam M, et al : Short. term treatment with sevelamer increases serum fetuin-A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 3 : 61-68, 2008
PubMed
48) Neven E, Dams G, Postnov A, et al : Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats. Nephrol Dial Transplant 24 : 1790-1799, 2009
PubMed
49) Toussaint ND, Lau KK, Polkinghorne KR, et al : Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in hemodialysis : A pilot randomized controlled trial. Nephrology (Carlton) 16 : 290-298, 2011
PubMed
50) Kalil RS, Flanigan M, Stanford W, et al : Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients : a prospective pilot study. Clin Nephrol 78 : 1-9, 2012
PubMed
51) Hoenderop JG, van der Kemp AW, Hartog A, et al : Molecular identification of the apical Ca2+ channel in 1, 25-dihydroxyvitamin D3-responsive epithelia. J Biol Chem 274 : 8375-8378, 1999
PubMed
52) Nikolov IG, Joki N, Nguyen-Khoa T, et al : Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nephrol Dial Transplant 27 : 505-513, 2012
PubMed
53) Maschio G, Tessitore N, D'Angelo A, et al : Early dietary phosphorus restriction and calcium supplementation in the prevention of renal osteodystrophy. Am J Clin Nutr 33 : 1546-1554, 1980
PubMed
54) Gutierrez OM, Mannstadt M, Isakova T, et al : Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359 : 584-592, 2008
PubMed
55) Guti6rrez OM, Januzzi JL, Isakova T, et al : Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119 : 2545-2552, 2009
 
56) Oliveira RB, Cancela AL, Graciolli FG, et al : Early control of PTH and FGF-23 in normophophatemic CKD patients : a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5 : 286-291, 2010
 
57) Isakova T, Guti6rrez OM, Chang Y, et al : Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20 : 388-396, 2009
 
58) Block GA, Raggi P, Bellasi A, et al : Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71 : 438-441, 2007
PubMed
59) Suki WN, Zabaneh R, Cangiano JL, et al : Effects of sevelamer and calciumbased phosphate binders on mortality in hemodialysis patients. Kidney Int 72 : 1130-1137, 2007
PubMed
60) Frazao JM, Adragao T : Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients : effects on vascular calcification, bone and a close look into the survival data. Kidney Int 111 (Suppl) : S38-S43, 2008
 
61) Chertow GM, Raggi P, Chasan-Taber S, et al : Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 19 : 1489-1496, 2004
 
62) Jamal SA, Fitchett D, Lok CE, et al : The effects of calcium-based versus non-calciumbased phosphate binders on mortality among patients with chronic kidney disease : a meta-analysis. Nephrol Dial Transplant 24 : 3168-3174, 2009
PubMed
63) Wilson R, Zhang P, Smyth M, et al : Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin 25 : 3021-3028, 2009
 
P.68 掲載の参考文献
1) 日本透析医学会 : わが国の慢性透析療法の現況2011年12月31日現在
 
2) 日本透析医学会 : わが国の慢性透析療法の現況2007年12月31日現在
 
3) 日本透析医学会 : わが国の慢性透析療法の現況2009年12月31日現在
 
4) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 日透析医会誌 45 : 301-356, 2012
 
5) 冨永芳博 : 二次性副甲状腺機能亢進症の外科治療. Clin Calcium 22 : 1083-1088, 2012
 
6) 冨永芳博 : わが国におけるSHPTに対するPTxの現況. 日透析医会誌 45 : 526, 2012
 
7) Komaba H, Nakanishi S, Fujimori A, et al : Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 5 : 2305-2314, 2010
 
8) Kakuta T, Tanaka R, Kanai G, et al : Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism? Ther Apher Dial 13 (Suppl 1) : S20-S27, 2009
 
9) Francisco RC, Aloha M, Ram6n PS : Effects of high-ef6ciency postdilution online hemodiafiltration and high-flux hemodialysis on serum phosphorus and cardiac structure and function in patients with end-stage renal disease. Int Urol Nephrol 2012. [Epub ahead of print］
 
10) Basile C, Libutti P, Di Turo AL, et al : Removal of uraemic retention solutes in standard bicarbonate haemodialysis and longhour slow-flow bicarbonate haemodialysis. Nephrol Dial Transplant 26 : 1296-1303, 2011
PubMed
11) Sampaio MS, Ruzany F, Dorigo DM, et al : Phosphate mass removal during hemodialysis : a comparison between eKT/V-matched conventional and extended dialysis. Am J Nephrol 36 : 121-126, 2012
PubMed
12) Basile C : Calcium mass balances in bicarbonate hemodialysis. Int J Nephrol 2011 : 540592, 2011
 
13) Young EW, Albert JM, Satayathum S, et al : Predictors and consequences of altered mineral metabolism : The Dialysis Outcomes and Practice Patterns Study. Kidney Int 67 : 1179-1187, 2005
 
14) Hwang JC, Chen CA, Wang CT, et al : Long-term effect of different dialysate calcium concentrations on parathyroid hormone levels in hemodialysis patients. Ren Fail 30 : 943-951, 2008
PubMed
15) LeBoeuf A, Mac-Way F, Utescu MS, et al : Impact of dialysate calcium concentration on the progression of aortic stiffness in patients on haemodialysis. Nephrol Dial Transplant 26 : 3695-3701, 2011
PubMed
16) Regidor DL, Kovesdy CP, Mehrotra R, et al : Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 19 : 2193-2203, 2008
 
17) Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al : Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 5 : 519-530, 2010
PubMed
18) 医歯薬出版編 : 最新日本食品成分表, 医歯薬出版 2010
 
19) 春木繁一 : 透析患者が期待する透析医療. 日透析医会誌 18 : 36-37, 2003
 
P.76 掲載の参考文献
1) Delmez JA, Slatopolsky E : Hyperphosphatemia : Its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 19 : 303-317, 1992
 
2) Block GA, Hulbert-Shearon TE, Levin NW, et al : Association of serum phosphorus and calcium×phosphate product with mortality risk in chronic hemodialysis patients : a national study. Am J Kidney Dis 31 : 607-617, 1998
 
3) Moe S, DrUeke T, Cunningham J, et al : Kidney Disease : Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006
PubMed
4) 栗原怜, 鈴木正司, 二瓶宏, 他 : 血液透析患者の高リン血症に対するリン結合剤PB-94 (Sevelamer Hydrochloride) の効果-第II相用量設定試験-. 腎と透析 55 : 221-238, 2003
 
5) 兵藤透, 平良隆保, 山本スミ子, 他 : 塩酸セベラマーの投与経験 (1) : 副作用としての便秘の克服. 泌尿器外科 18 : 239-247, 2005
Medical*Online
6) 栗原怜 : 塩酸セベラマーの副作用と安全な使用法. 腎と骨代謝 17 : 363-370, 2004
 
7) Akizawa T, Origasa H, Kameoka C, et al : A Phase III, Sevelamer HCl-controlled study of Bixalomer in chronic kidney disease patients on hemodialysis with hyperphosphatemia. American Society of Nephrology Kidney Week 2011 annual meeting, FR-PO1669
 
8) キックリン(R) カプセル250mg申請資料概要平成24年3月承認分
 
9) Mazzeo JR, Peters RM, Hanus MR, et al : A Phosphate binding assay for sevelamer hydrochloride by ion chromatography. J Pharm Biomed Anal 19 : 911-915, 1999
 
10) 松岡由美子, 岸千夏, 浅川ヒロ子, 他 : セベラマー塩酸塩服用方法の検討-服用時飲水量調節による便秘と腹部膨満感の回避の工夫. 透析ケア 15 : 94-100, 2009
 
11) 角田裕俊, 谷口圭一, 坂口ひとみ, 他 : リン酸吸着ポリマー製剤を服用量の水と混合したときの水分吸収量, 膨潤の程度, 粘度および流動性に関する比較検討. 臨床透析 28 : 251-256, 2012
 
12) 田添好恵, 池田真咲, 山口保子, 他 : 透析患者において内服量と飲水量は相関するか? 長崎県薬会誌 84 : 48-49, 2009
 
P.84 掲載の参考文献
1) 角田裕俊, 谷口圭一, 坂口ひとみ, 他 : リン酸吸着ポリマー製剤を服用量の水と混合したときの水分吸収量, 膨潤の程度, 粘度および流動性に関する比較検討. 臨床透析 28 : 251-256, 2012
 
2) Akizawa T, Origasa H, Kameoka C, et al : Randomized Controlled Trial of Bixalomer Versus Sevelamer Hydrochloride in Hemodialysis Patients With Hyperphosphatemia. Ther Apher Dial, in press.
 
3) Akizawa T, et al : Long-term Treatment of Bixalomer in Chronic Kidney Disease Patients on Hemodialysis with Hyperphosphatemia. Ther Apher Dial, in press.
 
P.90 掲載の参考文献
1) 高リン血症治療剤 (リン酸結合ポリマー) キックリンカプセル250mg, 添付文書, 2012年3月 (第1版), アステラス製薬 (株)
 
2) Akizawa T, Origasa H, Kameoka C, et al : A Phase III, Sevelamer HCI-controlled study of Bixalomer in chronic kidney disease patients on hemodialysis with hyperphosphatemia (Abstract). ASN Kidney Week 2011 annual meeting (Abstracts)
 
3) Akizawa T, Kameoka C : Long-Term treatment of Bixalomer in chronic kidney disease patients on hemodialysis with hyperphosphatemia. ASN Kidney Week 2011 annual meeting (Abstracts)
 
4) 古田賢司, 石原俊治, 佐藤秀一, 他 : 消化器症状を有する患者のQOL評価のための問診表「出雲スケール」の作成とその検証. 日本消化器病学会誌 106 : 1478-1487, 2009
 
5) 角田裕俊, 谷口圭一, 坂口ひとみ, 他 : リン酸吸着ポリマー製剤を服用量の水と混合した時の水分吸収量, 膨潤の程度, 粘度および流動性に関する比較検討. 臨床透析 28 : 251-256, 2012
 
6) 秋澤絵美, 山浦幸子, 青木匡, 他 : 正常ラットにおけるセベラマー塩酸塩及びビキサロマーの便及び腹部膨満に対する影響. 第24回日本腎性骨症研究会プログラム抄録集. p88, 2013
 
7) 栗原怜 : 塩酸セベラマーの副作用と安全な使用法. 腎と骨代謝 17 : 363-370, 2004
 
8) Sonikian MA, Pani IT, Iiopoulos AN, et al : Metabolic acidosis aggravation and hyperkalemia in hemodialysis patients treated by sevelamer hydrochloride. Ren Fail 27 : 143-147, 2005
PubMed
9) Oka Y, Miyazaki M, Takatsu S, et al : Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage. Ther Apher Dial 11 : 107-113, 2007
PubMed
10) 日本透析医学会 : わが国の慢性透析療法の現況, 2004年12月31日現在, CD-ROM版. 日本透析医学会, 東京, 2005
 
11) Wilkes BM, Reiner D, Kern M, et al : Simulataneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol 50 : 381-386, 1998
 
12) 日本透析医学会 : 図説 わが国の慢性透析療法の現況, 2004年12月31日現在. P50-55, 日本透析医学会, 東京, 2005
 
13) Di Iorio B, Di Micco L, Torraca S, et al : Acute effects of very-low-protein diet on FGF23 levels : A randomized study. Clin J Am Soc Nephrol 7 : 581-587, 2012
 
14) Koiwa F, Kazama JJ, Tokumoto A, et al : Sevelamer hydrochrolide and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 9 : 336-339, 2005
 
P.98 掲載の参考文献
1) National Kidney Foundation : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney failure. Am J Kidney Dis 42 (Suppl 3) : S1-S201, 2003
 
2) Noordzij M, Korevaar JC, Boeschoten EW, et al : The Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline for bone metabolism and disease in CKD : Association with mortality in dialysis patients. Am J Kidney Dis 46 : 925-932, 2005
PubMed
3) Guideline Working Group, Japanese Society for Dialysis Therapy : Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 12 : 514-525, 2008
 
4) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012
 
5) Block GA, Hulbert-Shearon TE, Levin NW, et al : Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients : a national study. Am J Kidney Dis 31 : 607-617, 1998
 
6) Lowrie EG, Lew NL : Death risk in hemodialysis patients : the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15 : 458-482, 1990
 
7) Blacher J, Guerin AP, Pannier B, et al : Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38 : 938-942, 2001
PubMed
8) Ganesh SK, Stack AG, Levin NW, et al : Association of elevated serum PO (4), Ca × PO (4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12 : 2131-2138, 2001
 
9) Block GA, Klassen PS, Lazarus JM, et al : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 : 2208-2218, 2004
PubMed
10) Slinin Y, Foley RN, Collins AJ : Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients : the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 16 : 1788-1793, 2005
 
11) Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, et al : Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 46 : 68-77, 2005
PubMed
12) Stevens LA, Djurdjev O, Cardew S, et al : Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality : evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15 : 770-779, 2004
PubMed
13) Young EW, Albert JM, Satayathum S, et al : Predictors and consequences of altered mineral metabolism : The Dialysis Outcomes and Practice Pattern Study. Kidney Int 67 : 1179-1187, 2005
 
14) Kalantar-Zadeh K, Kuwae N, Regidor DL, et al : Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70 : 771-780, 2006
PubMed
15) Taniguchi M, Fukagawa M, Fujii N, et al : The Apher Dial, in press
 
16) Danese MD, Belozeroff V, Smirnakis K, et al : Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 3 : 1423-1429, 2008
PubMed
17) Kimata N, Albert JM, Akiba T, et al : Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients : the Japan dialysis outcomes and practice patterns study. Hemodial Int 11 : 340-348, 2007
 
18) Fukagawa M, Yumita S, Akizawa T, et al : KRN1493 study group : Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23 : 328-335, 2008
 
P.105 掲載の参考文献
1) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012
 
2) Lin YF, Chien CT, Kan WC, et al : Pleiotoropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients : a randomized, open-label, paralled-group study. Clin Drug Investig 31 : 257-267, 2011
 
3) Block GA, Spiegel DM, Ehrlich J, et al : Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 : 1815-1824, 2005
PubMed
4) Kakuta T, Tanaka R, Hyodo T, et al : Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 57 : 422431, 2011
 
5) Block GA, Raggi P, Bellasi A, et al : Mortality effect of coronary artery calcification and phosphate binder choice in incident hemodialysis patients. Kideny Int 71 : 438-441, 2007
 
P.108 掲載の参考文献
1) Moe S, Drueke T, Cunningham J, et al : Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006
PubMed
2) Slinin Y, Foley RN, Collins AJ : Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients : the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 16 : 1788-1793, 2005
 
3) Danese MD, Belozeroff V, Smirnakis K, et al : Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 3 : 1423-1429, 2008
PubMed
4) Kimata N, Albert JM, Akiba T, et al : Association of mineral metabolism factors with all-cause and cardiovascular mortallty in hemodialysis patients : the Japan dialysis outcomes and practice patterns study. Hemodial Int 11 : 340-348, 2007
 
5) 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012
 
6) Guerin AP, London GM, Marchais SJ, et al : Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15 : 1014-1021, 2000
PubMed
7) Blacher J, Guerin AP, Pannier B, et al : Arterial calcifications, arterial stiffiness, and cardiovascular risk in end-stage renal disease. Hypertension 38 : 938-942, 2001
 
8) Takahashi N, Shoji T, Matsubara K, et al : Effect of histamine H2-receptor antagonist on the phosphorus-binding abilities of calcium carbonate and calcium lactate in hemodialysis patients. J Am Soc Nephrol 10 : 1090-1094, 1999
PubMed
9) Chertow GM, Burke SK, Raggi P : Treat to Goal Working Group : Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 : 245-252, 2002
 
10) Block GA, Spiegel DM, Ehrlich J, et al : Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 : 1815-1824, 2005
PubMed
11) 西原舞, 平田純生, 和泉智, 他 : 透析患者の便秘症についての実態調査. 透析会誌 37 : 1887-1892, 2004
 
12) Dimenas E, Glise H, Hallerback B, et al : Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 30 : 1046-1052, 1995
PubMed
P.113 掲載の参考文献
1) 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌 45 : 301-356, 2012
 
2) Kuro-o M, Matsumura Y, Aizawa H, et al : Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 : 45-51, 1997
PubMed
3) Kuro-o M : A potential link between phosphate and aging-lessons from Klotho-deficient mice. Mech Ageing Dev 131 : 270-275, 2010
PubMed
4) 草野英二・黒尾誠編 : 腎臓病から見えた老化の秘密. クロトー遺伝子の可能性. 日本医学館, 2011.
 
5) Sullivan C, Sayre SS, Leon JB, et al : Effect of food additives on hyperphosphatemia among patients with end-stage renal disease : a randomized controlled trial. JAMA 301 : 629-635, 2009
PubMed
6) Ritz E, Hahn K, Ketteler M, et al : Phosphate additives in food-a health risk. Dtsch Arztebl Int 109 : 49-55, 2012
PubMed
7) Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al : Understanding Sources of Dietary Phosphorus in the Treatment of Patients with Chronic Kidney Disease. Clin J Am Soc Nephrol 5 : 519-530, 2010
PubMed
8) Cheng SC, Young DO, Huang Y, et al : A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 3 : 1131-1138, 2008
 
9) Akizawa T, Kameoka C, Kaneko Y, et al : Long-term treatment of hyperphosphatemia with bixalomer in Japanese hemodialysis patients. Ther Apher Dial (in press). 2013.
 
10) Akizawa T, et al : Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Ther Apher Dial (in press). 2013.
 

書評

最近チェックした商品履歴

Loading...